BMI1 and brain neoplasm: Recently, the small‐molecule Bmi‐1 inhibitor PTC209, which exhibits selective post‐transcriptional properties, has shown promising therapeutic results in suppressing Bmi‐1 expression and mitigating self‐renewal in brain tumor cells [94, 95].